FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Robert Ozols

Research Profile

Disorders

Procedures

Chemicals & Drugs

Physiology

Drug Resistance

Concepts & Ideas

Co-author Network

Publications

TOP 3
Chad A Hamilton; Thomas Krivak; Maurie Markman; Austin Miller; Caela Miller; Robert F Ozols; G Scott Rose; Michael P Stany; Deborah K Armstrong; Mildred R Chernofsky; John H Farley; G Larry Maxwell
The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study.
Robert J Morgan; Ronald D Alvarez; Deborah K Armstrong; Barry Boston; Lee-May Chen; Larry Copeland; Jeff Fowler; David K Gaffney; David Gershenson; Benjamin E Greer; Perry W Grigsby; Laura Havrilesky; Carolyn M Johnston; Johnathan M Lancaster; Shashikant Lele; Ursula Matulonis; David O'Malley; Robert F Ozols; Steven W Remmenga; Paul Sabbatini; Julian Schink; Nelson Teng
Ovarian cancer. Clinical practice guidelines in oncology.
Robert F Ozols
Gynecologic Oncology Group (GOG-USA) trials in ovarian cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Robert Ozols (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Chad A Hamilton; Thomas Krivak; Maurie Markman; Austin Miller; Caela Miller; Robert F Ozols; G Scott Rose; Michael P Stany; Deborah K Armstrong; Mildred R Chernofsky; John H Farley; G Larry Maxwell
The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study.
Gynecologic oncology 2011;122(3):521-6.
2008: Robert J Morgan; Ronald D Alvarez; Deborah K Armstrong; Barry Boston; Lee-May Chen; Larry Copeland; Jeff Fowler; David K Gaffney; David Gershenson; Benjamin E Greer; Perry W Grigsby; Laura Havrilesky; Carolyn M Johnston; Johnathan M Lancaster; Shashikant Lele; Ursula Matulonis; David O'Malley; Robert F Ozols; Steven W Remmenga; Paul Sabbatini; Julian Schink; Nelson Teng
Ovarian cancer. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2008;6(8):766-94.
2008: Robert F Ozols
Gynecologic Oncology Group (GOG-USA) trials in ovarian cancer.
Advances in experimental medicine and biology 2008;622():131-43.
2007: Robert C Bast; J Tate Thigpen; Arbuck Susan; Karen Basen-Engquist; Laurie B Burke; Ralph Freedman; Sandra J Horning; Robert F Ozols; Gordon J Rustin; David Spriggs; Lari Wenzel; Richard Pazdur
Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.
Gynecologic oncology 2007;107(2):173-6.
2007: L M Hess; Richard R Barakat; C Tian; Robert F Ozols; David S Alberts
Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
Gynecologic oncology 2007;107(2):260-5.
2007: William E Winter; G Larry Maxwell; Chunqiao Tian; Jay W Carlson; Robert F Ozols; Peter G Rose; Maurie Markman; Deborah K Armstrong; Franco Muggia; William P McGuire
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(24):3621-7.
2007: Seiji Mabuchi; Deborah A Altomare; Mitchell Cheung; Lili Zhang; Poulikos I Poulikakos; Harvey H Hensley; Russell J Schilder; Robert F Ozols; Joseph R Testa
RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(14):4261-70.
2007: Robert C Bast; Molly Brewer; Changping Zou; Mary A Hernandez; Mary Daley; Robert F Ozols; Karen Lu; Zhen Lu; Donna Badgwell; Gordon B Mills; Steven J Skates; Zhen Zhang; Dan Chan; Anna Lokshin; Yinhua Yu
Prevention and early detection of ovarian cancer: mission impossible?
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2007;174():91-100.
2006: David S Alberts; Maurie Markman; Franco Muggia; Robert F Ozols; E Eldermire; Michael A Bookman; T Chen; J Curtin; L M Hess; Leonard Liebes; R C Young; E Trimble
Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer.
Gynecologic oncology 2006;103(3):783-92.
2006: Kathy Qi Cai; Andres Klein-Szanto; Devarajan Karthik; Mitchell I Edelson; Mary B Daly; Robert F Ozols; Henry T Lynch; Andrew K Godwin; Xiangxi Xu
Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations.
Gynecologic oncology 2006;103(2):719-28.
2006: Robert J Morgan; Ronald D Alvarez; Deborah K Armstrong; Lee-May Chen; Larry Copeland; Jeff Fowler; David K Gaffney; David M Gershenson; Benjamin E Greer; Carolyn M Johnston; Johnathan M Lancaster; Shashikant Lele; Ursula Matulonis; Robert F Ozols; Steven W Remmenga; Paul Sabbatini; John Soper; Nelson N Teng
Ovarian cancer. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4(9):912-39.
2006: Robert F Ozols; Michael A Bookman; Andreas du Bois; Jacobus Pfisterer; Alexander Reuss; Robert C Young
Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
Gynecologic oncology 2006;103(1):1-6.
2006: Robert F Ozols
Challenges for chemotherapy in ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17 Suppl 5():v181-7.
2006: Robert F Ozols; Michael A Bookman; Robert C Young
Intraperitoneal chemotherapy for ovarian cancer.
The New England journal of medicine 2006;354(15):1641-3; author reply 1641-3.
2006: Robert F Ozols
Systemic therapy for ovarian cancer: current status and new treatments.
Seminars in oncology 2006;33(2 Suppl 6):S3-11.
2005: Benjamin E Greer; Brian N Bundy; Robert F Ozols; Jeffrey M Fowler; Daniel L Clarke-Pearson; Robert A Burger; Robert S Mannel; Koen DeGeest; Ellen M Hartenbach; Rebecca N Baergen; Larry J Copeland
Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study.
Gynecologic oncology 2005;99(1):71-9.
2005: Robert F Ozols
Gemcitabine and carboplatin in second-line ovarian cancer.
Seminars in oncology 2005;32(4 Suppl 6):S4-8.
2005: Robert F Ozols
Treatment goals in ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15 Suppl 1():3-11.
2005: J B Vermorken; M K B Parmar; Mark F Brady; Elizabeth A Eisenhauer; T Hogberg; Robert F Ozols; J Rochon; Gordon J S Rustin; S Sagae; René H M Verheijen
Clinical trials in ovarian carcinoma: study methodology.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 8():viii20-viii29.
2004: Robert F Ozols
Counterpoint: Intraperitoneal chemotherapy: an investigational treatment in ovarian cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2004;2(6):555-60.
2004: Robert F Ozols
Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Journal of the National Comprehensive Cancer Network : JNCCN 2004;2 Suppl 2():S60-73.
2004: Mary B Daly; Robert F Ozols
Symptoms of ovarian cancer--where to set the bar?
JAMA : the journal of the American Medical Association 2004;291(22):2755-6.
2004: Robert F Ozols
Update on Gynecologic Oncology Group (GOG) trials in ovarian cancer.
Cancer investigation 2004;22 Suppl 2():11-20.
2004: Robert F Ozols; Michael A Bookman; Denise C Connolly; Mary B Daly; Andrew K Godwin; Russell J Schilder; Xiangxi Xu; Thomas C Hamilton
Focus on epithelial ovarian cancer.
Cancer cell 2004;5(1):19-24.
2003: Isabelle H Roland; Wan-Lin Yang; Dong-Hua Yang; Mary B Daly; Robert F Ozols; Thomas C Hamilton; Henry T Lynch; Andrew K Godwin; Xiangxi Xu
Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies.
Cancer 2003;98(12):2607-23.
2003: Michael A Bookman; Benjamin E Greer; Robert F Ozols
Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13(6):735-40.
2003: Michael A Bookman; Benjamin E Greer; Robert F Ozols
Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13 Suppl 2():149-55.
2003: Robert F Ozols; Brian N Bundy; Benjamin E Greer; Jeffrey M Fowler; Daniel L Clarke-Pearson; Robert A Burger; Robert S Mannel; Koen DeGeest; Ellen M Hartenbach; Rebecca Baergen
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(17):3194-200.
2003: Robert F Ozols; Mary B Daly; Andres Klein-Szanto; Thomas C Hamilton; Robert C Bast; Molly Brewer
Specific keynote: chemoprevention of ovarian cancer: the journey begins.
Gynecologic oncology 2003;88(1 Pt 2):S59-66; discussion S67-70.
2002: Robert F Ozols; Maurie Markman; J Tate Thigpen
ICON3 and chemotherapy for ovarian cancer.
Lancet 2002;360(9350):2086-7; author reply 2088.
2002: Robert F Ozols
Update on the management of ovarian cancer.
Cancer journal (Sudbury, Mass.) 2002;8 Suppl 1():S22-30.
2002: Mary B Daly; Robert F Ozols
The search for predictive patterns in ovarian cancer: proteomics meets bioinformatics.
Cancer cell 2002;1(2):111-2.
2002: Robert F Ozols
Future directions in the treatment of ovarian cancer.
Seminars in oncology 2002;29(1 Suppl 1):32-42.
2001: Robert F Ozols
The current role of gemcitabine in ovarian cancer.
Seminars in oncology 2001;28(2 Suppl 7):18-24.
2001: Russell J Schilder; James M Gallo; Michael Millenson; Michael A Bookman; Louis M Weiner; André Rogatko; B Rogers; K Padavic-Shallers; MP Boente; Norman G Rosenblum; Andrea L Adams; S Ciccotto; Robert F Ozols
Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(4):1183-94.
2000: J S Berek; Kamma Bertelsen; Andreas du Bois; Mark F Brady; J Carmichael; Elizabeth A Eisenhauer; M Gore; S Grenman; TC Hamilton; Steen W Hansen; P G Harper; G Horvath; SB Kaye; H J Lück; B Lund; William P McGuire; JP Neijt; Robert F Ozols; M K B Parmar; M J Piccart-Gebhart; R van Rijswijk; P Rosenberg; Gordon J S Rustin; C Sessa; J Tate Thigpen; C Tropé; MK Tuxen; I Vergote; J B Vermorken; P H Willemse
[Epithelial ovarian cancer (advanced stage): consensus conference (1998)].
Gynécologie, obstétrique & fertilité 2000;28(7-8):576-83.
2000: Robert F Ozols
Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty.
Seminars in oncology 2000;27(3 Suppl 7):47-9.
2000: Robert F Ozols
Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
Seminars in oncology 2000;27(3 Suppl 7):3-7.
2000: Robert F Ozols
The role of gemcitabine in the treatment of ovarian cancer.
Seminars in oncology 2000;27(1 Suppl 2):40-7.
2000: Corey J Langer; Cecilia McAleer; C A Bonjo; Samuel Litwin; Michael Millenson; R Kosierowski; K Blankstein; R Alexander; Robert F Ozols
Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC).
European journal of cancer (Oxford, England : 1990) 2000;36(2):183-93.
1999: Robert F Ozols
Chemotherapy for ovarian cancer.
Seminars in oncology 1999;26(6 Suppl 18):34-40.
1999: Robert F Ozols
Chemotherapy for ovarian cancer: beyond paclitaxel plus carboplatin.
The cancer journal from Scientific American 1999;5(6):336-8.
1999: Russell J Schilder; S Johnson; James Gallo; S Kindsfather; B Rogers; Michael A Bookman; Michael Millenson; MP Boente; Norman G Rosenblum; Samuel Litwin; Robert F Ozols
Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(7):2198-207.
1999: Corey J Langer; David R Gandara; Paula M Calvert; Martin J Edelman; Robert F Ozols
Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancer.
Seminars in oncology 1999;26(1 Suppl 4):12-8.
1999: Robert F Ozols
Paclitaxel plus carboplatin in the treatment of ovarian cancer.
Seminars in oncology 1999;26(1 Suppl 2):84-9.
1999: J S Berek; Kamma Bertelsen; Andreas du Bois; Mark F Brady; J Carmichael; Elizabeth A Eisenhauer; M Gore; S Grenman; TC Hamilton; Steen W Hansen; P G Harper; G Horvath; SB Kaye; H J Lück; B Lund; William P McGuire; JP Neijt; Robert F Ozols; M K B Parmar; M J Piccart-Gebhart; R van Rijswijk; P Rosenberg; Gordon J S Rustin; C Sessa; P H Willemse
Advanced epithelial ovarian cancer: 1998 consensus statements.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10 Suppl 1():87-92.
1999: Robert F Ozols; M Gore; C Tropé; S Grenman
Intraperitoneal treatment and dose-intense therapy in ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10 Suppl 1():59-64.
1999: William P McGuire; Mark F Brady; Robert F Ozols
The Gynecologic Oncology Group experience in ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10 Suppl 1():29-34.
1998: Corey J Langer; Paula M Calvert; Robert F Ozols
Gemcitabine and carboplatin in combination: phase I and phase II studies.
Seminars in oncology 1998;25(4 Suppl 9):51-4.
1998: William P McGuire; Robert F Ozols
Chemotherapy of advanced ovarian cancer.
Seminars in oncology 1998;25(3):340-8.
1998: Robert F Ozols
Chemotherapy of ovarian cancer.
Cancer treatment and research 1998;95():219-34.
1997: Michael A Bookman; Dwight D Kloth; P E Kover; S Smolinski; Robert F Ozols
Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Seminars in oncology 1997;24(6 Suppl 19):S19-13-S19-15.
1997: Robert F Ozols
Update of the NCCN ovarian cancer practice guidelines.
Oncology (Williston Park, N.Y.) 1997;11(11A):95-105.
1997: Robert F Ozols
Future directions in the chemotherapy of ovarian cancer.
Seminars in oncology 1997;24(5 Suppl 15):S15-86-S15-90.
1997: Corey J Langer; Michael Millenson; Elizabeth Rosvold; Samuel Litwin; Cecilia McAleer; C A Bonjo; Robert F Ozols
Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
Seminars in oncology 1997;24(4 Suppl 12):S12-81-S12-88.
1997: Michael A Bookman; Dwight D Kloth; P E Kover; S Smolinski; Robert F Ozols
Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(6):611-4.
1997: Robert F Ozols
Gynecologic oncology group trials in ovarian carcinoma.
Seminars in oncology 1997;24(1 Suppl 2):S2-10-S2-12.
1997: Robert F Ozols; J B Vermorken
Chemotherapy of advanced ovarian cancer: current status and future directions.
Seminars in oncology 1997;24(1 Suppl 2):S2-1-S2-9.
1997: S O'Reilly; Gini F Fleming; S D Barker; JANET WALCZAK; Michael A Bookman; William P McGuire; Russell J Schilder; R D Alvarez; Deborah K Armstrong; Ira R Horowitz; Robert F Ozols; Eric K Rowinsky
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):177-86.
1996: Corey J Langer; M Millenson; Peter J O'Dwyer; R Kosierowski; R Alexander; Samuel Litwin; Cecilia McAleer; C A Bonjo; Robert F Ozols
Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
Seminars in oncology 1996;23(6 Suppl 16):35-41.
1996: Michael A Bookman; W P McGuire; D Kilpatrick; Eileen Keenan; W M Hogan; S W Johnson; Peter J O'Dwyer; eric rowinsky; H H Gallion; Robert F Ozols
Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(6):1895-902.
1996: C K Obasaju; S W Johnson; André Rogatko; D Kilpatrick; J M Brennan; Thomas C Hamilton; Robert F Ozols; Peter J O'Dwyer; James M Gallo
Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(3):549-52.
1996: MP Boente; K Yeh; W M Hogan; Robert F Ozols
Current status of staging laparotomy in colorectal and ovarian cancer.
Cancer treatment and research 1996;82():337-57.
1996: J Leighton; J Clark; Bruce Giantonio; Robert F Ozols; Gary R Hudes
Genitourinary malignancy.
Cancer chemotherapy and biological response modifiers 1996;16():524-63.
1996: C P Schröder; A K Godwin; Peter J O'Dwyer; Kenneth D Tew; Thomas C Hamilton; Robert F Ozols
Glutathione and drug resistance.
Cancer investigation 1996;14(2):158-68.
1996: Peter J O'Dwyer; Thomas C Hamilton; F P LaCreta; James M Gallo; D Kilpatrick; T Halbherr; J Brennan; Michael A Bookman; J Hoffman; R C Young; R L Comis; Robert F Ozols
Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):249-56.
1996: A Hageboutros; Gary R Hudes; J Brennan; F Green; J Hoffman; F P LaCreta; J Colofiore; D S Martin; Robert F Ozols; Peter J O'Dwyer
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.
Cancer chemotherapy and pharmacology 1996;37(3):229-34.
1995: Robert F Ozols
Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer.
Seminars in oncology 1995;22(6 Suppl 15):1-6.
1995: Robert F Ozols
Outcome issues in ovarian cancer.
Oncology (Williston Park, N.Y.) 1995;9(11 Suppl):135-9.
1995: James M Gallo; J Brennan; Thomas C Hamilton; T Halbherr; P B Laub; Robert F Ozols; Peter J O'Dwyer
Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
Cancer research 1995;55(20):4507-11.
1995: Kang-Shen Yao; A K Godwin; S W Johnson; Robert F Ozols; Peter J O'Dwyer; Thomas C Hamilton
Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines.
Cancer research 1995;55(19):4367-74.
1995: Robert F Ozols
Current status of chemotherapy for ovarian cancer.
Seminars in oncology 1995;22(5 Suppl 12):61-6.
1995: Corey J Langer; J C Leighton; R L Comis; Peter J O'Dwyer; Cecilia McAleer; C A Bonjo; P F Engstrom; Samuel Litwin; S Johnson; Robert F Ozols
Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
Seminars in oncology 1995;22(4 Suppl 9):18-29.
1995: Corey J Langer; J C Leighton; R L Comis; Peter J O'Dwyer; Cecilia McAleer; C A Bonjo; P F Engstrom; Samuel Litwin; Robert F Ozols
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(8):1860-70.
1995: Robert F Ozols
Carboplatin and paclitaxel in ovarian cancer.
Seminars in oncology 1995;22(3 Suppl 6):78-83.
1995: Corey J Langer; J Leighton; Cecilia McAleer; R Comis; Peter J O'Dwyer; Robert F Ozols
Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
Seminars in oncology 1995;22(3 Suppl 6):64-9.
1995: DC Schultz; Lisa Vanderveer; K H Buetow; MP Boente; Robert F Ozols; Thomas C Hamilton; A K Godwin
Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.
Cancer research 1995;55(10):2150-7.
1995: Peter J O'Dwyer; Thomas C Hamilton; Kang-Shen Yao; Kenneth D Tew; Robert F Ozols
Modulation of glutathione and related enzymes in reversal of resistance to anticancer drugs.
Hematology/oncology clinics of North America 1995;9(2):383-96.
1995: Russell J Schilder; MP Boente; BW Corn; R M Lanciano; R C Young; Robert F Ozols
The management of early ovarian cancer.
Oncology (Williston Park, N.Y.) 1995;9(2):171-82; discussion 185-7.
1995: Gary R Hudes; R Kosierowski; R Greenberg; H E Ramsey; S C Fox; Robert F Ozols; Cecilia McAleer; Bruce Giantonio
Phase II study of topotecan in metastatic hormone-refractory prostate cancer.
Investigational new drugs 1995;13(3):235-40.
1995: N B Haas; Russell J Schilder; S Nash; Louis M Weiner; R C Catalano; Robert F Ozols; Peter J O'Dwyer
A phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer.
Investigational new drugs 1995;13(3):229-33.
1995: A Hageboutros; André Rogatko; E M Newman; Cecilia McAleer; J Brennan; F P LaCreta; Gary R Hudes; Robert F Ozols; Peter J O'Dwyer
Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
Cancer chemotherapy and pharmacology 1995;35(3):205-12.
1994: Robert F Ozols
Research directions in epithelial ovarian cancer.
Gynecologic oncology 1994;55(3 Pt 2):S168-73.
1994: BW Corn; R M Lanciano; MP Boente; W M Hunter; J Ladazack; Robert F Ozols
Recurrent ovarian cancer. Effective radiotherapeutic palliation after chemotherapy failure.
Cancer 1994;74(11):2979-83.
1994: S W Johnson; P A Swiggard; L M Handel; J M Brennan; A K Godwin; Robert F Ozols; Thomas C Hamilton
Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
Cancer research 1994;54(22):5911-6.
1994: F P Lacreta; J M Brennan; Thomas C Hamilton; Robert F Ozols; Peter J O'Dwyer
Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer.
Drug metabolism and disposition: the biological fate of chemicals 1994;22(6):835-42.
1994: Robert F Ozols
Treatment of ovarian cancer: current status.
Seminars in oncology 1994;21(2 Suppl 2):1-9; quiz 10, 58.
1994: N B Haas; F P LaCreta; J Walczak; Gary R Hudes; J M Brennan; Robert F Ozols; Peter J O'Dwyer
Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
Cancer research 1994;54(5):1220-6.
1994: S W Johnson; R P Perez; A K Godwin; anthony yeung; L M Handel; Robert F Ozols; Thomas C Hamilton
Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines.
Biochemical pharmacology 1994;47(4):689-97.
1994: Robert F Ozols
Carboplatin and Taxol (paclitaxel) in advanced ovarian carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 6():S39-43.
1994: Gary R Hudes; Robert F Ozols; Bruce Giantonio
Genitourinary malignancy.
Cancer chemotherapy and biological response modifiers 1994;15():531-54.
1993: Thomas C Hamilton; Peter J O'Dwyer; Robert F Ozols
Platinum analogues in preclinical and clinical development.
Current opinion in oncology 1993;5(6):1010-6.
1993: K Hamaguchi; A K Godwin; M Yakushiji; Peter J O'Dwyer; Robert F Ozols; Thomas C Hamilton
Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Cancer research 1993;53(21):5225-32.
1993: Robert F Ozols
[Epithelial cancer of the ovary: current data].
Bulletin du cancer 1993;80(11):955-70.
1993: J M Brennan; Peter J O'Dwyer; Robert F Ozols; F P LaCreta
High-performance liquid chromatographic determination of the S- and R-diastereoisomers of L-buthionine (SR)-sulfoximine in human plasma and urine.
Journal of chromatography 1993;620(1):121-8.
1993: Robert F Ozols; Peter J O'Dwyer; Thomas C Hamilton
Clinical reversal of drug resistance in ovarian cancer.
Gynecologic oncology 1993;51(1):90-6.
1993: K Yao; A K Godwin; Robert F Ozols; Thomas C Hamilton; Peter J O'Dwyer
Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment.
Cancer research 1993;53(16):3662-6.
1993: N B Haas; J B Hines; Gary R Hudes; N Johnston; Robert F Ozols; Peter J O'Dwyer
Phase I trial of 5-fluorouracil by 24-hour infusion weekly.
Investigational new drugs 1993;11(2-3):181-5.
1993: R P Perez; Thomas C Hamilton; Robert F Ozols; R C Young
Mechanisms and modulation of resistance to chemotherapy in ovarian cancer.
Cancer 1993;71(4 Suppl):1571-80.
1993: S W Johnson; Robert F Ozols; Thomas C Hamilton
Mechanisms of drug resistance in ovarian cancer.
Cancer 1993;71(2 Suppl):644-9.
1993: Robert F Ozols; J T Thigpen; J Dauplat; N Colombo; Martine J Piccart; Kamma Bertelsen; L Levin; B Lund
Advanced ovarian cancer. Dose intensity.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4 Suppl 4():49-56.
1993: Bruce Giantonio; Robert F Ozols; Gary R Hudes
Genitourinary malignancy.
Cancer chemotherapy and biological response modifiers 1993;14():498-529.
1992: Peter J O'Dwyer; F P LaCreta; Russell J Schilder; S Nash; Cecilia McAleer; L L Miller; Gary R Hudes; Robert F Ozols
Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(8):1352-8.
1992: Robert F Ozols
Chemotherapy for advanced epithelial ovarian cancer.
Hematology/oncology clinics of North America 1992;6(4):879-94.
1992: R P Perez; S L Nash; Robert F Ozols; R L Comis; Peter J O'Dwyer
Phase II study of amonafide in advanced and recurrent sarcoma patients.
Investigational new drugs 1992;10(2):99-101.
1992: Peter J O'Dwyer; Thomas C Hamilton; R C Young; F P LaCreta; N Carp; Kenneth D Tew; K Padavic; R L Comis; Robert F Ozols
Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results.
Journal of the National Cancer Institute 1992;84(4):264-7.
1992: Robert F Ozols
New developments with carboplatin in the treatment of ovarian cancer.
Seminars in oncology 1992;19(1 Suppl 2):85-9.
1992: E Rosvold; Russell J Schilder; J Walczak; S M DiFino; P J Flynn; T K Banerjee; W J Heim; P F Engstrom; Robert F Ozols; Peter J O'Dwyer
Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
Cancer chemotherapy and pharmacology 1992;29(4):305-8.
1992: Robert F Ozols
Role of carboplatin in ovarian cancer. Current results and thoughts for the future.
Acta obstetricia et gynecologica Scandinavica. Supplement 1992;155():75-7.
1992: Robert F Ozols
Role of chemotherapy in the future treatment of ovarian cancer.
Acta obstetricia et gynecologica Scandinavica. Supplement 1992;155():55-60.
1992: Russell J Schilder; Robert F Ozols
New therapies for ovarian cancer.
Cancer investigation 1992;10(4):307-15.
1992: Robert F Ozols
Advances in the chemotherapy of gynecologic malignancies.
Hematological oncology 1992;10(1):43-51.
1991: Peter J O'Dwyer; Gary R Hudes; J Colofiore; J Walczak; J Hoffman; F P LaCreta; R L Comis; D S Martin; Robert F Ozols
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
Journal of the National Cancer Institute 1991;83(17):1235-40.
1991: Robert F Ozols; R C Young
Ovarian cancer: where to next?
Seminars in oncology 1991;18(3):307-10.
1991: Robert F Ozols; R C Young
Chemotherapy of ovarian cancer.
Seminars in oncology 1991;18(3):222-32.
1991: R P Perez; A K Godwin; Thomas C Hamilton; Robert F Ozols
Ovarian cancer biology.
Seminars in oncology 1991;18(3):186-204.
1991: R P Perez; Peter J O'Dwyer; L M Handel; Robert F Ozols; Thomas C Hamilton
Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.
International journal of cancer. Journal international du cancer 1991;48(2):265-9.
1991: Robert F Ozols
Ovarian cancer: new clinical approaches.
Cancer treatment reviews 1991;18 Suppl A():77-83.
1991: Peter J O'Dwyer; A R Paul; Gary R Hudes; J Walczak; Robert F Ozols; R L Comis
Phase II study of amonafide (nafidamide, NSC 308847) in advanced colorectal cancer.
Investigational new drugs 1991;9(1):65-7.
1990: Robert F Ozols; Peter J O'Dwyer; Thomas C Hamilton; R C Young
The role of glutathione in drug resistance.
Cancer treatment reviews 1990;17 Suppl A():45-50.
1990: Russell J Schilder; L Hall; Anne Monks; L M Handel; A J Fornace; Robert F Ozols; Antonio Tito Fojo; Thomas C Hamilton
Metallothionein gene expression and resistance to cisplatin in human ovarian cancer.
International journal of cancer. Journal international du cancer 1990;45(3):416-22.
1990: Thomas C Hamilton; Robert F Ozols; M B Dabrow
Multidrug resistance to alkylating agents and platinum compounds: state of our knowledge.
Oncology (Williston Park, N.Y.) 1990;4(3):101-6; discussion 106, 109.
1990: R P Perez; Thomas C Hamilton; Robert F Ozols
Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems.
Pharmacology & therapeutics 1990;48(1):19-27.
1989: Robert F Ozols
Cisplatin dose intensity.
Seminars in oncology 1989;16(4 Suppl 6):22-30.
1989: Robert F Ozols
Optimal dosing with carboplatin.
Seminars in oncology 1989;16(2 Suppl 5):14-8.